Clinical trial
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
NCT00246974 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00246974 |
|---|---|
| Title | Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT |
| Official title | An Open Randomised Phase II Study Of Gemcitabine Plus Cisplatin +/- Concomitant or Sequential ZD1839 in Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Cisplatin, Gefitinib |
| Enrollment | 125 |
| Start date | May 1, 2003 |
| Primary completion | Oct 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Nov 1, 2005 |
| Last update posted | Oct 15, 2008 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: